Saint Roch Veterinary, LLC, a Fort Wayne clinic and subsidiary of Topikos Scientific, Inc., announced on Jan. 29, 2025, the public unveiling of GingiGuard™, a novel compound the clinic says is designed to treat canine periodontal disease while avoiding systemic exposure.

In a release and accompanying materials published Jan. 29, Saint Roch described GingiGuard™ as a patented new molecular entity (NME) intended to correct microbial imbalance in the oral cavity. The company said the compound “selectively disrupts dysbiosis by harnessing the advanced technology of its patents‑issued, NME (New Molecular Entity).” Saint Roch described the approach as targeted action in the mouth that avoids systemic effects, rather than a systemically delivered therapy.

Saint Roch reported results from tests that involved 140 privately owned dogs of diverse ages and breeds. According to the announcement, animals were essentially free of gingivitis and observable signs of periodontal disease four weeks following a single topical application; the release lists that four‑week observation period as 672 hours. Observers in the study reported that treated dogs’ gingiva were restored to a normal position and appearance and that halitosis — commonly cited by owners as bad breath — disappeared after treatment.

The clinic named two staff members as affiliated with the project: Dr. Kevin Cawood, DVM, and Dr. Mike Bechill, PhD. Saint Roch identified Topikos Scientific, Inc. as its corporate parent and provided additional program background and materials on the clinic’s website, where the company said more detailed information is available for veterinarians and pet owners.

The announcement emphasized that the treated cohort consisted of privately owned pets rather than animals from shelters or research colonies, and that the group included a wide mix of ages and breeds. Saint Roch characterized the observed effects — normalization of gingival position and elimination of halitosis — as primary, measurable outcomes at the end of the four‑week window following one application.

Canine periodontal disease is among the most common conditions affecting dogs. Detailed studies indicate that around 80% or more of dogs over 2–3 years of age are affected, and researchers have noted the condition’s potential to produce chronic inflammation and infection that extend beyond the mouth. Clinical signs frequently associated with dental problems in dogs include bad breath, visible tartar on teeth, slow or difficult eating, pawing at the mouth, loose or missing teeth, excessive drooling, swollen or bleeding gums, and weight loss — many of which Saint Roch said improved in the treated cohort.

In its release, Saint Roch positioned GingiGuard™ as an alternative or complementary tool to existing dental care strategies. The announcement did not present the product as replacing standard preventative measures. Public guidance from veterinary sources typically recommends measures such as daily tooth brushing with pet‑safe toothpaste, use of VOHC‑approved dental diets, chews or water additives to reduce plaque and tartar, and regular veterinary oral exams with professional cleanings under anesthesia; Saint Roch said it intends GingiGuard™ to work alongside established clinical care rather than as a substitute for routine prevention. Preventative measures can pet owners take to maintain their dog’s dental health.

Saint Roch disclosed the timeline of public presentation on Jan. 29, 2025, and reiterated that the single‑application protocol produced measurable improvements at the four‑week check. The clinic and parent company made research materials and program details available on their website for veterinary review. No additional peer‑reviewed data or independent study results were included in the release; Saint Roch’s communication focused on the reported outcomes in its privately owned cohort and the compound’s mechanism targeting oral dysbiosis.

The announcement and supporting material can be found on Saint Roch Veterinary’s website, where the clinic provides background on its practice and the GingiGuard™ program.

Source

Original reporting: view the original article.